

Mitochondria-Longevity Research in Switzerland Q3 2021

was compiled to give a detailed systematic description of the **innovative approaches for regulating mitochondrial function to control Human Longevity and treat some systemic disorders**. This analytical case study focuses on **BioTech, Pharmaceutical and Healthcare companies**, and **R&D institutions in Switzerland** and their partnerships, predicting the development of the relevant market and determining the degree of technology relevance. In addition, a unique database was compiled for the systematic review of key stakeholders in the industry.

All the technologies described in the analytical case study are already available, in use, and ready for further research.

The Mitochondria Targets and Biomarkers are selected by their **clinical efficacy** and create the most relevant modern precedent for safe and effective human experimentation and validation that the Longevity Industry can apply.

Mitochondria-Longevity Research in Switzerland

Special Analytical Case Study
Q3 2021

www.aginganalytics.com/mitochondria-in-switzerland

The separate chapter of the report is devoted to the **overview of companies in Switzerland** that are developing different technologies to enhance the mitochondrial longevity capacity. Overall, this analytical case study offers a **one-stop expert evaluation of a novel and dynamic industry**, particularly in Switzerland, with high growth potential.

100+

Companies

120

Investors

30

R&D Centres

7

Leading Companies
in Switzerland

About Aging Analytics Agency

Aging Analytics Agency is the world's premier provider of industry analytics on the topics of Longevity, Precision Preventive Medicine and Economics of Aging, and the convergence of technologies such as AI, Blockchain, Digital Health, and their impact on healthcare industry.

Our Value Proposition:

Open Access and Proprietary Analytical Case Studies

Aging Analytics Agency is producing regular open-access reports covering emerging longevity markets – technologies, innovations, companies, and trends. Our clients and partners can enjoy access to proprietary reports featuring additional in-depth research conducted by our team on a regular basis.

IT-Platform and Big Data Analytics Dashboard

Our company is building a sophisticated cloud-based engine for advanced market and business intelligence in the longevity biotech, medicine, finance, and governance industries. It includes a data mining engine, infrastructure for expert data curation, and advanced visualization dashboards, including mindmaps, knowledge graphs, and 3-dimensional visualizations.

Strategic Consulting

Aging Analytics Agency offers a comprehensive range of consulting services, conducting customized case studies, research, and analytics for internal (organizational) use, tailored to the precise needs of specific clients. It includes a wide range of market and competitor research services, technology scouting and due diligence, investment landscape profiling, and comprehensive analytics support for decision-making.


Key Takeaways

- In Switzerland only 15 clinical trials for study of mitochondrial function are provided for the last 10 years: 8 trials for therapeutic programmes, 3 - dietary supplements, 3 - behavioral study.
- Many of the BioTech companies in the country are connected to **the University of Lausanne (UNIL)**, as well as the renowned **Swiss Federal Institute of Technology Lausanne (EPFL)**. The pharmaceutical companies, **Nestle, Roche** and **Novartis**, also provide fundamental research and study therapeutic targets of mitochondrial dysfunction.
- A spin-off of EPFL, **Amazentis**, is developing anti-ageing products based on a **uroolithin A**, targeting **PINK1**, which has been shown to improve the mitophagia process. The company is conducting clinical trials using this molecule to target **age-related muscle decline**, or **sarcopenia**, which affects many people as they grow older.
- In **30-40% of cases**, the **Cellvie**, a Harvard spin-off founded in the US with headquarters in Zurich, pioneering **therapeutic mitochondria transplantation**. Employing proprietary preparation and delivery techniques, Cellvie is transplanting mitochondria directly into compromised cells. The company has now set out to bring it about as a new treatment modality in **ischemia-reperfusion injury, ageing, and beyond**.
- **Research & Development centres** focus on the treatment of **muscle dysfunction, neurodegenerative disorders, obesity, wound healing**, etc. R&D centres create a important background for BioTech companies. So, the **new mitochondrial approach** in Swiss BioTech market will be intensively developed in the next few years.

Mitochondria in Longevity: Switzerland Overview Q3 2021

Companies – 100+
Investors – 120
R&D Centres – 30

Companies
Investors
R&D Centres



Leading Companies of the Mitochondria-Longevity Industry in Switzerland

